Prospective study to assess the association of the treatment outcomes and the quality of life in advanced urothelial carcinoma
Latest Information Update: 21 Dec 2021
Price :
$35 *
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 21 Dec 2021 New trial record